



Patent Application
Attorney Docket No. PC25466A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 2nd day of June 2005.

By

(Signature of person mailing)

Kristina L. Konstas

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Shalaby W. Shalaby, et al. :

APPLICATION NO.: 10/693,307 : Examiner: Not Known

FILING DATE: October 31, 2002 : Group Art Unit: Not Known

TITLE: LIQUID CONJUGATES OF SOLID :
PHARMACEUTICALS

MS: Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

1. PCT International Search Report, PCT/IB0304698.
2. U.S. 4,831,031, May 16, 1989, Lowe, III, et al.
3. U.S. 6,221,958 B1, April 24, 2001, Shalaby, et al.
4. U.S. 5,653,992, August 5, 1997, Bezwada, et al.
5. U.S. 5,714,159, February 3, 1998, Shalaby
6. U.S. 6,413,539 B1, July 2, 2002, Shalaby
7. U.S. 5,612,652, May 18, 1997, Crosby
8. U.S. 5,672,659, September 30, 1997, Shalaby et al.
9. U.S. 5,821,221, October 13, 1998, Shalaby et al.

10. U.S. 6,204,256 B1, March 20, 2001, Shalaby et al.
11. U.S. 5,916,883, June 29, 1999, Shalaby et al.
12. U.S. 5,863,985, January 26, 1999, Shalaby et al.
13. U.S. 6,469,132 B1, October 22, 2002, Eisenberg Adi, et al.,
14. WO 01/82970 A, November 8, 2001, Macromed Inc.
15. WO 99/18142 A, April 15, 1999, Macromed Inc.
16. WO 00/66085 A, November 9, 2000, Macromed Inc.
17. WO 91/16887 A, November 14, 1991, Res Triangle Inst.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date:


June 2, 2005

Respectfully submitted,



Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)573 -6380



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PC25466A

SERIAL NO. 10/693,307

APPLICANT Shalaby W. Shalaby, et al.

FILING DATE October 31, 2002

GROUP Not Known

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	4	8	3	1	0	3	1	05/16/89	Lowe, III, et al.			
	B	6	2	2	1	9	5	8	04/24/02	Shalaby et al.	B1		
	C	5	6	5	3	9	9	2	08/05/97	Bezwada et al.			
	D	5	7	1	4	1	5	9	02/03/98	Shalaby			
	E	6	4	1	3	5	3	9	07/02/02	Shalaby	B1		
	F	5	6	1	2	6	5	2	03/18/97	Crosby			
	G	5	8	2	1	2	2	1	10/13/98	Shalaby et al.			
	H	6	2	0	4	2	5	6	03/20/01	Shalaby et al.	B1		
	I	5	8	6	3	9	8	5	01/26/99	Shalaby et al.			
	J	6	4	6	9	1	3	2	10/22/02	Adi, et al.			
	K												

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	L	0	1	8	2	9	7	0	11/08/01	WO			
	M	9	9	1	8	1	4	2	04/15/99	WO			
	N	0	0	6	6	0	8	5	11/09/00	WO			
	O	9	1	1	6	8	8	7	11/14/91	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.